Boston Partners cut its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 19.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 512,976 shares of the medical research company’s stock after selling 124,947 shares during the quarter. Boston Partners’ holdings in Amgen were worth $216,142,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the business. Quest 10 Wealth Builders Inc. raised its holdings in Amgen by 220.0% in the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 55 shares in the last quarter. Wellington Altus USA Inc. boosted its stake in Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 34 shares during the last quarter. Nvwm LLC increased its stake in shares of Amgen by 412.5% during the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after purchasing an additional 66 shares during the last quarter. PFS Partners LLC grew its position in shares of Amgen by 95.5% during the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 42 shares in the last quarter. Finally, TOWER TRUST & INVESTMENT Co purchased a new position in Amgen in the 3rd quarter worth $38,000. 76.50% of the stock is owned by institutional investors and hedge funds.
Amgen Stock Down 1.1%
Shares of NASDAQ AMGN opened at $438.82 on Friday. The stock has a market capitalization of $237.36 billion, a price-to-earnings ratio of 25.45, a P/E/G ratio of 3.09 and a beta of 0.43. Amgen Inc. has a 12-month low of $312.39 and a 12-month high of $483.99. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. The firm’s 50-day moving average price is $429.28 and its 200-day moving average price is $383.32.
Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The company had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter last year, the business posted $5.64 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 23.37 EPS for the current fiscal year.
Amgen Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen’s payout ratio is currently 58.47%.
Analysts Set New Price Targets
Several brokerages have recently weighed in on AMGN. UBS Group increased their price objective on shares of Amgen from $470.00 to $530.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Argus increased their price objective on shares of Amgen from $460.00 to $515.00 and gave the company a “buy” rating in a research report on Thursday, November 12th. Royal Bank Of Canada upped their price objective on shares of Amgen from $430.00 to $470.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. boosted their target price on Amgen from $350.00 to $425.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 4th. Finally, Barclays upped their price target on Amgen from $400.00 to $430.00 and gave the stock an “equal weight” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average price target of $428.62.
Read Our Latest Stock Analysis on AMGN
Amgen Company Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Featured Articles
- Five stocks we like better than Amgen
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
